Atorvastatin pre-exposure in hypercholesterolemia remedies 27HC mediated dendritic cell dysfunctions in triple-negative breast cancer
Molecular Therapy Oncology · 2026-09 · 34 (3) · 201250
DOI: 10.1016/j.omton.2026.201250 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Oncology, 2026-09. Verfasst von Pritha Roy Choudhury und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute (CNCI), Kolkata, West Bengal 700026, India. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chittaranjan National Cancer Institute, Indian Council of Medical Research, CSIR - Human Resource Development Group.
Abstract (Originalsprache)
Early inception of hypercholesterolemia has led to prevalent statin pre-exposure among cancer patients. Furthermore, emerging associations between increased circulating cholesterol, dyslipidemia, and cancer recurrence have spurred the repurposing of statins to combat cancer. However, the mechanistic impact of statin pre-exposure on cancer progression remains unclear. Here, our retrospective study with triple-negative breast cancer (TNBC) patients showed that atorvastatin pre-exposure promotes recurrence-free survival. Atorvastatin pre-exposure in TNBC patients and a preclinical high-fat diet-induced hypercholesterolemic murine tumor model lowered intratumoral 27-hydroxycholesterol (27HC) concentration, as estimated by LC-MS/MS. Within the tumor microenvironment, elevated 27HC interacted with estrogen receptor alpha (ERα) on dendritic cells (DCs), hindering DC maturation, migration, and antigen presentation. Atorvastatin reduced ERα expression on DCs and remediated 27HC-ERα-induced DC dysfunctions, improved DC-mediated T cell priming, thereby facilitating tumor restriction when adoptively transferred to 4T1-bearing NOD/SCID/IL2Rγ-/- mice. Targeted intratumoral knockdown of cyp27a1 (rate-determining enzyme for 27HC production) alongside atorvastatin pre-exposure uplifted cDC1 functionality. Atorvastatin pre-treatment exerts its action by reducing the availability of intratumoral 27HC and expression of ERα on DCs, which eventually enhances DC functionality and restores their efficiency to prime anti-tumor CD8+ T cell responses. Therefore, atorvastatin pre-exposure adjunct to 27HC-ERα inhibition may serve as an effective immunotherapeutic intervention in TNBC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute (CNCI), Kolkata, West Bengal 700026, India.
- Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar, Punjab 160062, India.
- Division of Cancer Biology, CSIR-Central Drug Research Institute, Lucknow Uttar Pradesh 226031, India.
- Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar, Punjab 160062, India.
- Department of Medical Oncology, Apollo Multispecialty Hospitals, Kolkata, West Bengal 700054, India.
- Department of Pharmaceutical Technology (Biotechnology), National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar, Punjab 160062, India.
Förderung
- Chittaranjan National Cancer Institute
- Indian Council of Medical Research
- CSIR - Human Resource Development Group
- Israel Atomic Energy Commission
- University Grants Commission
- Council of Scientific and Industrial Research, India
Zitieren
APA
Choudhury, P. R., Chakravarti, M., Bera, S., Arora, P., Sultana, J., Khan, M. A., Biradar, R., Guha, A., Dhar, S., Ghosh, I., Ganguly, N., Lasure, A., Kashyap, P., Das, J., Mandal, B., Das, P., Sarkar, A., Datta, D., Nandi, S., …, & Bose, A. (2026). Atorvastatin pre-exposure in hypercholesterolemia remedies 27HC mediated dendritic cell dysfunctions in triple-negative breast cancer. Molecular Therapy Oncology, 34(3), 201250. https://doi.org/10.1016/j.omton.2026.201250
Vancouver
Choudhury PR, Chakravarti M, Bera S, Arora P, Sultana J, Khan MA, et al. Atorvastatin pre-exposure in hypercholesterolemia remedies 27HC mediated dendritic cell dysfunctions in triple-negative breast cancer. Molecular Therapy Oncology. 2026;34(3):201250. doi:10.1016/j.omton.2026.201250
BibTeX
@article{Choudhury2026,
author = {Choudhury, Pritha Roy and Chakravarti, Mohona and Bera, Saurav and Arora, Pooja and Sultana, Jasmine and Khan, Muqtada Ali and Biradar, Rushikesh and Guha, Aishwarya and Dhar, Sukanya and Ghosh, Indranil and Ganguly, Nilanjan and Lasure, Aarti and Kashyap, Priyanka and Das, Juhina and Mandal, Biswajit and Das, Prodipto and Sarkar, Anirban and Datta, Dipak and Nandi, Sukhendu and Alam, Neyaz and Baral, Rathindranath and Banerjee, Saptak and Bose, Anamika},
title = {Atorvastatin pre-exposure in hypercholesterolemia remedies 27HC mediated dendritic cell dysfunctions in triple-negative breast cancer},
journal = {Molecular Therapy Oncology},
year = {2026},
volume = {34},
number = {3},
pages = {201250},
doi = {10.1016/j.omton.2026.201250}
}
EUVIMED